Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer
Primary bone cancers (PBC) belong to the family of mesenchymal tumors classified based on their cellular origin, extracellular matrix, genetic regulation, and epigenetic modification. The three major PBC types, Ewing sarcoma, osteosarcoma, and chondrosarcoma, are frequently aggressive tumors, highly...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-04-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137422000094 |
| _version_ | 1811234288845193216 |
|---|---|
| author | Danh D. Truong Salah-Eddine Lamhamedi-Cherradi Joseph A. Ludwig |
| author_facet | Danh D. Truong Salah-Eddine Lamhamedi-Cherradi Joseph A. Ludwig |
| author_sort | Danh D. Truong |
| collection | DOAJ |
| description | Primary bone cancers (PBC) belong to the family of mesenchymal tumors classified based on their cellular origin, extracellular matrix, genetic regulation, and epigenetic modification. The three major PBC types, Ewing sarcoma, osteosarcoma, and chondrosarcoma, are frequently aggressive tumors, highly metastatic, and typically occur in children and young adults. Despite their distinct origins and pathogenesis, these sarcoma subtypes rely upon common signaling pathways to promote tumor progression, metastasis, and survival. The IGF/PI3K/mTOR and AXL/YAP/TAZ pathways, in particular, have gained significant attention recently given their ties to oncogenesis, cell fate and differentiation, metastasis, and drug resistance. Naturally, these pathways – and their protein constituents – have caught the eye of the pharmaceutical industry, and a wide array of small molecule inhibitors and antibody drug-conjugates have emerged. Here, we review how the IGF/PI3K/mTOR and AXL/YAP/TAZ pathways promote PBC and highlight the drug candidates under clinical trial investigation. |
| first_indexed | 2024-04-12T11:35:14Z |
| format | Article |
| id | doaj.art-31fb45c8660145638ba30ebdba72258e |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-04-12T11:35:14Z |
| publishDate | 2022-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-31fb45c8660145638ba30ebdba72258e2022-12-22T03:34:52ZengElsevierJournal of Bone Oncology2212-13742022-04-0133100419Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancerDanh D. Truong0Salah-Eddine Lamhamedi-Cherradi1Joseph A. Ludwig2Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USADepartment of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USACorresponding author.; Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USAPrimary bone cancers (PBC) belong to the family of mesenchymal tumors classified based on their cellular origin, extracellular matrix, genetic regulation, and epigenetic modification. The three major PBC types, Ewing sarcoma, osteosarcoma, and chondrosarcoma, are frequently aggressive tumors, highly metastatic, and typically occur in children and young adults. Despite their distinct origins and pathogenesis, these sarcoma subtypes rely upon common signaling pathways to promote tumor progression, metastasis, and survival. The IGF/PI3K/mTOR and AXL/YAP/TAZ pathways, in particular, have gained significant attention recently given their ties to oncogenesis, cell fate and differentiation, metastasis, and drug resistance. Naturally, these pathways – and their protein constituents – have caught the eye of the pharmaceutical industry, and a wide array of small molecule inhibitors and antibody drug-conjugates have emerged. Here, we review how the IGF/PI3K/mTOR and AXL/YAP/TAZ pathways promote PBC and highlight the drug candidates under clinical trial investigation.http://www.sciencedirect.com/science/article/pii/S2212137422000094AXLBone cancerEwing sarcomaOsteosarcomaChondrosarcomaIGF-1R |
| spellingShingle | Danh D. Truong Salah-Eddine Lamhamedi-Cherradi Joseph A. Ludwig Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer Journal of Bone Oncology AXL Bone cancer Ewing sarcoma Osteosarcoma Chondrosarcoma IGF-1R |
| title | Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer |
| title_full | Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer |
| title_fullStr | Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer |
| title_full_unstemmed | Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer |
| title_short | Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer |
| title_sort | targeting the igf pi3k mtor pathway and axl yap1 taz pathways in primary bone cancer |
| topic | AXL Bone cancer Ewing sarcoma Osteosarcoma Chondrosarcoma IGF-1R |
| url | http://www.sciencedirect.com/science/article/pii/S2212137422000094 |
| work_keys_str_mv | AT danhdtruong targetingtheigfpi3kmtorpathwayandaxlyap1tazpathwaysinprimarybonecancer AT salaheddinelamhamedicherradi targetingtheigfpi3kmtorpathwayandaxlyap1tazpathwaysinprimarybonecancer AT josephaludwig targetingtheigfpi3kmtorpathwayandaxlyap1tazpathwaysinprimarybonecancer |